Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into Opportunities

This publication has 8 references indexed in Scilit:

• Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor–based Dual Combination Therapy
  European Urology Oncology, 2022
• Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial
  European Urology, 2021
• Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
  New England Journal of Medicine, 2021
• Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma
  European Urology Oncology, 2021
• Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
  European Journal of Cancer, 2021
• Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?
  JNCI: Journal of the National Cancer Institute, 2021
• Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?
  European Urology, 2020
• Neoadjuvant therapy for localized and locally advanced renal cell carcinoma
  Urologic Oncology: Seminars and Original Investigations, 2018